Premium
Weekly vinblastine in pediatric low‐grade glioma patients with carboplatin allergic reaction
Author(s) -
LafayCousin Lucie,
Holm Stefan,
Qaddoumi Ibrahim,
Nicolin Gary,
Bartels Ute,
Tabori Uri,
Huang Annie,
Bouffet Eric
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21091
Subject(s) - carboplatin , medicine , vinblastine , desensitization (medicine) , regimen , toxicity , chemotherapy , oncology , pharmacology , cisplatin , receptor
Abstract BACKGROUND Carboplatin‐based regimens have demonstrated activity in unresectable low‐grade glioma (LGG) in children. Despite an interesting toxicity profile, the use of these regimens has been limited by the development of carboplatin hypersensitivity reaction (HSR) in up to 30% of patients. Desensitization has been the recommended approach for HSR. However, no guidelines have existed to aid physicians when carboplatin desensitization techniques fail. METHODS A pilot study of monotherapy with weekly vinblastine for LGG in 9 children who developed carboplatin HSR on a carboplatin and vincristine regimen was performed. RESULTS Vinblastine toxicity was moderate and readily manageable. None of the 9 patients had disease progression on therapy. Magnetic resonance imaging evaluation of tumor size from diagnosis to the end of vinblastine treatment showed 1 complete response (CR), 1 partial response (PR), 5 objective effects (OE), and 2 stable diseases (SD). CONCLUSIONS This experience suggested that weekly vinblastine has a good efficacy to toxicity ratio in the treatment of LGG and can be a valuable option for children who develop severe HSR. Cancer 2005. © 2005 American Cancer Society.